RWM
ACAD icon

Rialto Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Rialto Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253 Buy
10
+2
+25% +$44 ﹤0.01% 1832
2026
Q1 		$179 Sell
8
-4
-33% -$96 ﹤0.01% 1616
2025
Q4 		$321 Buy
12
+5
+71% +$119 ﹤0.01% 1412
2025
Q3 		$150 Buy
7
+5
+250% +$118 ﹤0.01% 1545
2025
Q2 		$44 Buy
+2
New +$37 ﹤0.01% 1647

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rialto Wealth Management's ACAD Position: Q2 2026 in Review

Rialto Wealth Management increased its Acadia Pharmaceuticals (ACAD) stake by 25% in Q2 2026, buying an estimated $44 and bringing the position to 10 shares worth $253. The position accounts for ﹤0.01% of the portfolio, ranked #1832.

Rialto Wealth Management first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. The position peaked at $321 in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Rialto Wealth Management held 10 shares of Acadia Pharmaceuticals worth $253 as of Q2 2026.
  • Rialto Wealth Management bought 2 Acadia Pharmaceuticals shares in Q2 2026, an estimated $44.
  • Acadia Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1832 holding.
  • Rialto Wealth Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Rialto Wealth Management's Acadia Pharmaceuticals position peaked at $321 in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.